Haegarda® (C1 esterase inhibitor [human]) – New orphan drug approval
June 22, 2017 – The FDA announced the approval of CSL Behring’s Haegarda (C1 esterase inhibitor [C1-INH] [human]) for subcutaneous injection, indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.
Top